Value of the Pitt bacteremia score in predicting the outcome of non-bacteremic patients with infections caused by multidrug-resistant organisms.

Publication date: Jul 07, 2026

Infections caused by multidrug-resistant organisms (MDROs) are increasingly associated with significant morbidity and mortality. Early identification of high-risk patients is essential. The Pitt Bacteremia Score (PBS) is validated in bloodstream infections, but its role in non-bacteremic infections remains unclear. To evaluate the performance of the PBS in predicting mortality among patients with non-bacteremic MDRO infections and compare it with the quick Sequential Organ Failure Assessment (qSOFA) score and the Charlson Comorbidity Index (CCI). We conducted a 5-year retrospective study at a tertiary care center including adults (>18 years) admitted between December 2018 and December 2023 with confirmed non-bacteremic MDRO infections. Organisms included methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Enterobacterales (CRE), and carbapenem-resistant Acinetobacter baumannii (CRAB). Patients with bloodstream infection, colonization, ICU stay >48 hours, severe COVID-19, or terminal illness were excluded. Separate multivariable logistic regression models were constructed for PBS, qSOFA, and CCI. Discriminatory performance was assessed using receiver operating characteristic (ROC) curve analysis. Among 202 patients (mean age 62. 1 +/- 18. 3 years; 67. 8% male), in-hospital mortality was 21. 3%. In multivariable analyses, PBS (aOR 1. 75, 95% CI 1. 49-2. 05; p

Open Access PDF

Semantics

Original Article